Viking Therapeutics (VKTX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Viking Therapeutics

NasdaqCM•Healthcare•Biotechnology

$28.70-0.66(-0.02%)Market open

Market Cap

$3.41B

P/B

8.4x

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

How this company scores

WeakMetricSide Score: 33/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (5/25).

Profitability5/25

Growth7/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 8.4x5y range 1.3x – 10.1x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $3.41B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-560.02M
TTM Op. Income: $-560.02M
Q. Op. Income: $-132.60M
TTM Net Income: $-534.80M
Q. Net Income: $-128.02M
EPS: $-1.1
Shares Out.: $116.26M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-560.02M and TTM operating income of $-560.02M show growth is flowing through to the bottom line. However, net income is negative at $534.80M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -13259700000.0%
Net Margin: -12802200000.0%

Op. margin of -13259700000.0% is down 5802300000.0% YoY — costs are rising relative to revenue. Net margin at -12802200000.0% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 8.4x

P/S of 0.0x and P/B of 8.4x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $521.90M
Cash: $125.75M
Long-Term Debt: N/A
Book Value: $408.32M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-125.17M
TTM Free Cash Flow: $-418.44M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-418.44M on $-125.17M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 7 consecutive quarters — a weakening trend.